HLA-G +3027多态性与儿童霍奇金淋巴瘤的肿瘤复发相关。
HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma.
作者信息
De Re Valli, Caggiari Laura, Mussolin Lara, d'Amore Emanuele Stefano, Famengo Barbara, De Zorzi Mariangela, Martina Lia, Elia Caterina, Pillon Marta, Santoro Nicola, Muggeo Paola, Buffardi Salvatore, Bianchi Maurizio, Sala Alessandra, Farruggia Piero, Vinti Luciana, Carosella Edgardo D, Burnelli Roberta, Mascarin Maurizio
机构信息
Immunopathology and Cancer Biomarkers, Department of Translational Research, CRO Aviano National Cancer Institute, Aviano, Italy.
Clinic of Pediatric Hemato-Oncology, Department of Women's and Children's Health, University of Padova, Institute of Paediatric Research Fondazione Città della Speranza, Padova, Italy.
出版信息
Oncotarget. 2017 Nov 18;8(62):105957-105970. doi: 10.18632/oncotarget.22515. eCollection 2017 Dec 1.
In this study, we tested whether polymorphisms in human leukocyte antigen G (HLA-G) were associated with event-free survival (EFS) in pediatric Hodgkin's lymphoma (HL). We evaluated the association of HLA-G 3'-UTR polymorphisms with EFS in 113 pediatric HL patients treated using the AIEOP LH-2004 protocol. Patients with the +3027-C/A genotype (rs17179101, UTR-7 haplotype) showed lower EFS than those with the +3027-C/C genotype (HR= 3.23, 95%CI: 0.99-10.54, P=0.012). Female patients and systemic B symptomatic patients with the HLA-G +3027 polymorphism showed lower EFS. Multivariate analysis showed that the +3027-A polymorphism (HR 3.17, 95%CI 1.16-8.66, P=0.025) was an independent prognostic factor. Immunohistochemical analysis showed that HL cells from patients with the +3027-C/A genotype did not express HLA-G. Moreover, HLA-G +3027 polymorphism improved EFS prediction when added to the algorithm for therapeutic group classification of pediatric HL patients. Our findings suggest HLA-G +3027 polymorphism is a prognostic marker in pediatric HL patients undergoing treatment according to LH-2004 protocol.
在本研究中，我们测试了人类白细胞抗原G（HLA-G）基因多态性是否与儿童霍奇金淋巴瘤（HL）的无事件生存期（EFS）相关。我们评估了113例采用AIEOP LH - 2004方案治疗的儿童HL患者中HLA-G 3'-UTR多态性与EFS的关联。携带+3027-C/A基因型（rs17179101，UTR-7单倍型）的患者的EFS低于携带+3027-C/C基因型的患者（HR = 3.23，95%CI：0.99 - 10.54，P = 0.012）。携带HLA-G +3027多态性的女性患者和有全身B症状的患者的EFS较低。多变量分析显示，+3027-A多态性（HR 3.17，95%CI 1.16 - 8.66，P = 0.025）是一个独立的预后因素。免疫组织化学分析显示，携带+3027-C/A基因型患者的HL细胞不表达HLA-G。此外，当将HLA-G +3027多态性添加到儿童HL患者治疗组分类算法中时，可改善EFS预测。我们的研究结果表明，HLA-G +3027多态性是根据LH - 2004方案接受治疗的儿童HL患者的一个预后标志物。
Zotero 插件